CN112891642A - 一种生物因子涂层支架及其制备方法 - Google Patents
一种生物因子涂层支架及其制备方法 Download PDFInfo
- Publication number
- CN112891642A CN112891642A CN202110108199.XA CN202110108199A CN112891642A CN 112891642 A CN112891642 A CN 112891642A CN 202110108199 A CN202110108199 A CN 202110108199A CN 112891642 A CN112891642 A CN 112891642A
- Authority
- CN
- China
- Prior art keywords
- stent
- coating
- biological factor
- hep
- pda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 75
- 239000011248 coating agent Substances 0.000 title claims abstract description 73
- 239000003181 biological factor Substances 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229920001690 polydopamine Polymers 0.000 claims abstract description 40
- 229960003638 dopamine Drugs 0.000 claims abstract description 29
- 229920000669 heparin Polymers 0.000 claims abstract description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 23
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 22
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 19
- 230000003511 endothelial effect Effects 0.000 claims abstract description 17
- 210000000130 stem cell Anatomy 0.000 claims abstract description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960002897 heparin Drugs 0.000 claims abstract description 13
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 12
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 12
- 229910052751 metal Inorganic materials 0.000 claims abstract description 12
- 239000002184 metal Substances 0.000 claims abstract description 12
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910001000 nickel titanium Inorganic materials 0.000 claims abstract description 7
- 238000006845 Michael addition reaction Methods 0.000 claims abstract description 5
- 239000002262 Schiff base Substances 0.000 claims abstract description 5
- 150000004753 Schiff bases Chemical class 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 230000002427 irreversible effect Effects 0.000 claims abstract description 5
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002953 phosphate buffered saline Substances 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 230000010118 platelet activation Effects 0.000 claims description 7
- 230000003068 static effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000002474 experimental method Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 108010087230 Sincalide Proteins 0.000 claims description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000001218 confocal laser scanning microscopy Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 206010053567 Coagulopathies Diseases 0.000 claims description 3
- 238000000516 activation analysis Methods 0.000 claims description 3
- 230000035602 clotting Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000003124 biologic agent Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 3
- 210000002889 endothelial cell Anatomy 0.000 abstract description 11
- 206010002329 Aneurysm Diseases 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 8
- 230000005012 migration Effects 0.000 abstract description 7
- 238000013508 migration Methods 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 201000008450 Intracranial aneurysm Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 210000001956 EPC Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000000386 Hypertensive Intracranial Hemorrhage Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
本发明属于医疗器械技术领域,公开了一种生物因子涂层支架及其制备方法,包括:PDA涂层的Ni‑Ti支架;肝素钠涂层的DA支架;VEGF涂层的DA‑Hep支架;抗CD34抗体涂层的DA‑Hep支架;不含肝素的支架;同时装载PDA、生物因子和肝素的支架。利用多巴胺DA自聚合形成聚多巴胺PDA,在金属表面与金属形成不可逆的有机络合物,使PDA作为连接支架与生物因子媒介涂层;在支架表面构建成聚多巴胺PDA涂层后,利用席夫碱反应和迈克尔加成依次加载肝素Hep、血管内皮生长因子VEGF和抗CD34抗体,获得生物因子涂层支架。本发明有效地捕获血液循环中的内皮祖细胞,促进动脉瘤颈周围的内皮细胞增殖与迁移。
Description
技术领域
本发明属于医疗器械技术领域,尤其涉及一种生物因子涂层支架及其制备方法。
背景技术
目前,颅内动脉瘤破裂出血是仅次于脑梗塞及高血压性脑出血的第三位的脑卒中原因,患病率约3%,对人类的生命威胁极大。而目前用以治疗颅内动脉瘤的支架均为裸支架,不能很好的促进瘤颈的内皮化,导致应用支架治疗后动脉瘤的复发率仍高于10%以上。因此,亟需一种新的生物因子涂层支架及其制备方法。
通过上述分析,现有技术存在的问题及缺陷为:目前用以治疗颅内动脉瘤的支架均为裸支架,不能很好的促进瘤颈的内皮化,导致应用支架治疗后动脉瘤的复发率仍高于10%以上。
解决以上问题及缺陷的难度为:为了解决内皮化不足的问题,现有的方法是不断增加了裸支架的金属履盖率,如密网孔支架的的应用,较以往非密网孔的支架的内皮化作用更强了,但内皮化作用仍未达到理想的效果,有的案例在1年甚至是5年仍未达到完全内皮化;另外,不断增加的金属履盖率增加了血栓事件的发生概率,从而也限制了该类型的支架在一些脑血管中的应用,且密网孔支架的植入手术难度远远大于非密网孔支架。如何在支架表面达到快速内皮化作用且兼具良好的生物相溶性成为该研究的难点。本发明选用VEGF、抗CD34抗体作为内皮化的关键因子,它们分别通过促原位内皮细胞的增殖与迁移、扑获循环中的内皮祖细胞的作用机制在支架上较快速的形成内皮化,将VEGF、抗CD34抗体及肝素稳定地涂层在支架上且平稳的释放又成为该研究的关键点。
解决以上问题及缺陷的意义为:该生物涂层支架具有快速的促内皮作用及理想的生物相溶性,其意义在于该发明很可能将使得支架具备更佳的内皮化用用,明显缩短动脉瘤的治愈时间、提高动脉瘤的治愈率,而且显著降低其植入血管后的致血栓性,因而缩短抗血小板药物的使用时间及降低其使用强度,从而进一步减少相关并发症的发生。
发明内容
针对目前临床上广泛应用的裸支架存在的不足,本发明提供了一种生物因子涂层支架及其制备方法。
本发明是这样实现的,一种生物因子涂层支架,所述生物因子涂层支架包括:具有PDA涂层的Ni-Ti支架(简称DA);具有肝素钠涂层的DA支架(简称DA-Hep);具有VEGF涂层的DA-Hep支架(简称为DA-VEGF-Hep);具有抗CD34抗体涂层的DA-Hep支架(简称为DA-CD34-Hep);不含肝素的支架(表示为DA-VEGF/CD34);同时装载PDA、生物因子和肝素的支架(表示DA-VEGF/CD34-Hep)。本发明的另一目的在于提供一种应用所述的生物因子涂层支架的生物因子涂层支架的制备方法,所述生物因子涂层支架的制备方法包括以下步骤:
步骤一,将多巴胺溶解于Tris-Hcl缓冲溶液(10.0mM,pH=8.5)中,制成2mg/mL的多巴胺溶液。然后,将Ni-Ti材质的支架浸入多巴胺溶液中。摇匀24小时后,用去离子水冲洗支架,再干燥24小时,得到涂有PDA的支架(简称DA)。
步骤二,在支架表面构建成聚多巴胺PDA涂层后,将肝素钠溶液(5mg/mL,pH=7.2)滴入DA支架中,持续1h。然后将支架样品冲洗干燥(简称DA-Hep)。
步骤三,对于构建VEGF涂层,在4℃下,将DA-Hep支架样品用1.0μg/mL VEGF溶液浸泡48小时,然后用磷酸盐缓冲盐水缓冲液(PBS)冲洗,得到DA-VEGF-Hep样品,晾干备用。
对于构建抗CD34抗体涂层,DA-Hep支架样品用2.0μg/mL抗CD34抗体溶液在4℃条件下浸泡48小时,用PBS缓冲液冲洗后晾干,得到DA-CD34-Hep。
为了实验的目的,本发明还制作了不含肝素的支架(表示为DA-VEGF/CD34)和同时装载PDA、生物因子和肝素的支架(表示DA-VEGF/CD34-Hep)进行比较。
进一步,所述生物因子涂层支架的表征及分析方法还包括:激光共聚焦(LSCM)分析支架表面涂层的负载情况;接触角分析;血小板激活分析以及凝血时间分析;蛋白质吸附释放实验分析;使用酶标仪进行OD值测量细胞增殖速率,并使用SPSS22.0统计数据。
进一步,电子显微镜以及CCK-8细胞计数曲线,确定所述生物因子涂层支架在静态环境和动态环境下内皮祖细胞的捕获能力。
结合上述的所有技术方案,本发明所具备的优点及积极效果为:本发明提供的生物因子涂层支架,利用多巴胺(DA)自聚合形成聚多巴胺(PDA),可以在金属表面与金属形成不可逆的有机络合物的原理,使PDA作为连接支架与生物因子媒介涂层;在支架表面构建成聚多巴胺(PDA)涂层后,利用席夫碱反应和迈克尔加成依次加载肝素(Hep)、血管内皮生长因子(VEGF)和抗CD34抗体,具备更好的生物相容性,并且能够有效地捕获血液循环中的内皮祖细胞和促进动脉瘤颈周围的内皮细胞增殖与迁移。
本发明构建得到的生物因子涂层支架,在细胞实验层面证实了它相比现在临床上所使用的裸支架具有更好的生物相容性、更有效的内皮细胞促增殖效果和更强效的内皮祖细胞捕获能力;在生物相容性方面,新的生物因子涂层支架相对比裸支架有了明显的提高,它的水接触角下降至0°;血小板激活率下降了10%;APTT延长超过180s,PT延长超过3s;蛋白吸附率从903.9μg/cm2下降至39.5μg/cm2。
本发明对内皮细胞的影响方面,无论是对内皮细胞的促迁移作用还是促增殖作用,生物因子涂层支架均表现得更高效,使用酶标仪进行OD值测量细胞增殖速率,并使用SPSS22.0统计数据后,上述实验结果均有统计学意义(P<0.05)。
本发明在对内皮祖细胞的影响方面,生物因子涂层支架无论是在静态环境或者动态环境下,相对于裸支架都具备更强的内皮祖细胞捕获能力。通过扫描电镜以及CCK-8细胞计数曲线,在静态环境下,裸支架捕获的内皮祖细胞为2205/cm2,少于生物因子涂层支架的11540/cm2(P<0.05);而在动态环境下,裸支架仅捕获到1802/cm2,而生物因子涂层支架则为9420/cm2(P<0.05)。
总之,本发明所具备的优点及积极效果为:使颅内支架具备更好的生物相容性,并且能够有效地捕获血液循环中的内皮祖细胞和促进动脉瘤颈周围的内皮细胞增殖与迁移,从而达到快速内皮化的作用。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对本发明实施例中所需要使用的附图做简单的介绍,显而易见地,下面所描述的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下还可以根据这些附图获得其他的附图。
图1是本发明实施例提供的生物因子涂层支架及其制备方法流程图。
图2是本发明实施例提供的生物因子涂层支架及其制备方法原理图。
图3是本发明实施例提供的对比效果图;A支架表面的水接触角大幅度下降;B加载有肝素钠的DA-VEGF/CD34-Hep组的血小板激活率为88.9%,对比其他三组有明显下降(P<0.05);C加载有肝素钠的DA-VEGF/CD34-Hep组的APTT时间明显延长,大于180s,PT时间相较于其他三组时间延长大于3s(延长时间>3s有意义);D对比空白组,随着多巴胺、VEGF、抗CD34、肝素钠的逐层负载,材料表面对牛血清白蛋白的粘附从空白组平均每单位面积吸附903.9μg白蛋白,到DA组638.6μg/cm2,DA-VEGF/CD34组383.7μg/cm2,最后到DA-VEGF/CD34-Hep下降至39.5μg/cm2(P<0.05)。
图4是本发明实施例提供的新型生物因子涂层支架的LSCM图。
图5是本发明实施例提供的新型生物因子涂层支架捕获EPCs实验示意图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
针对现有技术存在的问题,本发明提供了一种生物因子涂层支架及其制备方法,下面结合附图对本发明作详细的描述。
本发明实施例提供的生物因子涂层支架包括:具有PDA涂层的Ni-Ti支架(简称DA);具有肝素钠涂层的DA支架(简称DA-Hep);具有VEGF涂层的DA-Hep支架(简称DA-VEGF-Hep);具有抗CD34抗体涂层的DA-Hep支架(简称DA-CD34-Hep);不含肝素的支架(表示为DA-VEGF/CD34)和同时装载PDA、生物因子和肝素的支架(简称DA-VEGF/CD34-Hep)。
如图1所示,本发明实施例提供的生物因子涂层支架的制备方法包括以下步骤:
S101,利用多巴胺DA自聚合形成聚多巴胺PDA,在金属表面与金属形成不可逆的有机络合物,使PDA作为连接支架与生物因子媒介涂层;
S102,在支架表面构建成聚多巴胺PDA涂层后,利用席夫碱反应和迈克尔加成依次加载肝素Hep、血管内皮生长因子VEGF和抗CD34抗体,获得生物因子涂层支架。
本发明提供的生物因子涂层支架的制备方法业内的普通技术人员还可以采用其他的步骤实施,图1的本发明提供的生物因子涂层支架的制备方法仅仅是一个具体实施例而已。
本发明实施例提供的生物因子涂层支架及其制备方法原理图如图2所示。
本发明具体包括以下步骤:
步骤一,将多巴胺溶解于Tris-Hcl缓冲溶液(10.0mM,pH=8.5)中,制成2mg/mL的多巴胺溶液。然后,将Ni-Ti材质的支架浸入多巴胺溶液中。摇匀24小时后,用去离子水冲洗支架,再干燥24小时,得到涂有PDA的支架(简称DA)。
步骤二,在支架表面构建成聚多巴胺PDA涂层后,将肝素钠溶液(5mg/mL,pH=7.2)滴入DA支架中,持续1h。然后将支架样品冲洗干燥(简称DA-Hep)。
步骤三,对于构建VEGF涂层,在4℃下,将DA-Hep支架样品用1.0μg/mL VEGF溶液浸泡48小时,然后用磷酸盐缓冲盐水缓冲液(PBS)冲洗,得到DA-VEGF-Hep样品,晾干备用。
对于构建抗CD34抗体涂层,DA-Hep支架样品用2.0μg/mL抗CD34抗体溶液在4℃条件下浸泡48小时,用PBS缓冲液冲洗后晾干,得到DA-CD34-Hep。
为了实验的目的,本发明还制作了不含肝素的支架(表示为DA-VEGF/CD34)和同时装载PDA、生物因子和肝素的支架(表示DA-VEGF/CD34-Hep)进行比较。
进一步,所述生物因子涂层支架的表征及分析方法还包括:激光共聚焦(LSCM)分析支架表面涂层的负载情况;接触角分析;血小板激活分析以及凝血时间分析;蛋白质吸附释放实验分析;使用酶标仪进行OD值测量细胞增殖速率,并使用SPSS22.0统计数据。
进一步,电子显微镜以及CCK-8细胞计数曲线,确定所述生物因子涂层支架在静态环境和动态环境下内皮祖细胞的捕获能力。
下面结合实施例对本发明的技术方案作进一步的描述。
针对目前临床上广泛应用的裸支架存在的不足,本发明构建了生物因子涂层支架,它具备更好的生物相容性,并且能够有效地捕获血液循环中的内皮祖细胞和促进动脉瘤颈周围的内皮细胞增殖及迁移。
1、发明内容
(1)利用多巴胺(DA)自聚合形成聚多巴胺(PDA),可以在金属表面与金属形成不可逆的有机络合物的原理,使PDA作为连接支架与生物因子媒介涂层。
(2)在支架表面构建成聚多巴胺(PDA)涂层后,利用席夫碱反应和迈克尔加成依次加载肝素(Hep)、血管内皮生长因子(VEGF)和抗CD34抗体。
2、技术效果
(1)通过上述技术构建出生物因子涂层支架,本发明在细胞实验层面证实了它相比现在临床上所使用的裸支架具有更好的生物相容性、更有效的内皮细胞促增殖效果和更强效的内皮祖细胞捕获能力。
(2)在生物相容性方面,新的生物因子涂层支架相对比裸支架有了明显的提高,它的水接触角下降至0°;血小板激活率下降了10%;APTT延长超过180s,PT延长超过3s;蛋白吸附率从903.9μg/cm2下降至39.5μg/cm2。
对内皮细胞的影响方面,无论是对内皮细胞的促迁移作用还是促增殖作用,生物因子涂层支架均表现得更高效,使用酶标仪进行OD值测量细胞增殖速率,并使用SPSS22.0统计数据后,上述实验结果均有统计学意义(P<0.05)。
在对内皮祖细胞的影响方面,生物因子涂层支架无论是在静态环境或者动态环境下,相对于裸支架都具备更强的内皮祖细胞捕获能力。通过扫描电镜以及CCK-8细胞计数曲线,在静态环境下,裸支架捕获的内皮祖细胞为2205/cm2,少于生物因子涂层支架的11540/cm2(P<0.05);而在动态环境下,裸支架仅捕获到1802/cm2,而生物因子涂层支架则为9420/cm2(P<0.05)。
下面结合实验对本发明的技术效果作详细的描述。
如图3所示,A支架表面的水接触角大幅度下降;B加载有肝素钠的DA-VEGF/CD34-Hep组的血小板激活率为88.9%,对比其他三组有明显下降(P<0.05);C加载有肝素钠的DA-VEGF/CD34-Hep组的APTT时间明显延长,大于180s,PT时间相较于其他三组时间延长大于3s(延长时间>3s有意义);D对比空白组,随着多巴胺、VEGF、抗CD34、肝素钠的逐层负载,材料表面对牛血清白蛋白的粘附从空白组平均每单位面积吸附903.9μg白蛋白,到DA组638.6μg/cm2,DA-VEGF/CD34组383.7μg/cm2,最后到DA-VEGF/CD34-Hep下降至39.5μg/cm2(P<0.05)。
图4显示本发明的生物因子涂层支架构建方法使裸支架上均匀涂覆了生物因子,表明支架成功负载VEGF或抗CD34抗体。
图5表明DA-CD34-Hep支架捕获EPCs能力最强,且新型生物因子涂层支架比裸支架更能促进HUVECS增殖。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,都应涵盖在本发明的保护范围之内。
Claims (7)
1.一种生物因子涂层支架的制备方法,其特征在于,所述生物因子涂层支架的制备方法包括:
利用多巴胺DA自聚合形成聚多巴胺PDA,在金属表面与金属形成不可逆的有机络合物,使PDA作为连接支架与生物因子媒介涂层;
在支架表面构建成聚多巴胺PDA涂层后,利用席夫碱反应和迈克尔加成依次加载肝素Hep、血管内皮生长因子VEGF和抗CD34抗体,获得生物因子涂层支架。
2.如权利要求1所述的生物因子涂层支架的制备方法,其特征在于,所述生物因子涂层支架的制备方法还包括:使用酶标仪进行OD值测量细胞增殖速率,并使用SPSS22.0统计数据。
3.如权利要求1所述的生物因子涂层支架的制备方法,其特征在于,所述生物因子涂层支架的制备方法还包括:通过扫描电镜以及CCK-8细胞计数曲线,确定所述生物因子涂层支架在静态环境和动态环境下内皮祖细胞的捕获能力。
4.如权利要求1所述的生物因子涂层支架的制备方法,其特征在于,所述生物因子涂层支架的制备方法具体包括:
步骤一,将多巴胺溶解于Tris-Hcl缓冲溶液10.0mM,pH=8.5中,制成2mg/mL的多巴胺溶液;将Ni-Ti材质的支架浸入多巴胺溶液中。摇匀24小时后,用去离子水冲洗支架,再干燥24小时,得到涂有PDA的支架;
步骤二,在支架表面构建成聚多巴胺PDA涂层后,将肝素钠溶液5mg/mL,pH=7.2滴入DA支架中,持续1h;将支架样品冲洗干燥;
步骤三,对于构建VEGF涂层,在4℃下,将DA-Hep支架样品用1.0μg/mL VEGF溶液浸泡48小时,然后用磷酸盐缓冲盐水缓冲液PBS冲洗,得到DA-VEGF-Hep样品,晾干备用。
5.如权利要求4所述的生物因子涂层支架的制备方法,其特征在于,所述生物因子涂层支架的制备方法构建抗CD34抗体涂层,DA-Hep支架样品用2.0μg/mL抗CD34抗体溶液在4℃条件下浸泡48小时,用PBS缓冲液冲洗后晾干,得到DA-CD34-Hep。
6.如权利要求1所述的生物因子涂层支架的制备方法,其特征在于,所述生物因子涂层支架的制备方法的生物因子涂层支架的表征及分析方法还包括:激光共聚焦LSCM分析支架表面涂层的负载情况;接触角分析;血小板激活分析以及凝血时间分析;蛋白质吸附释放实验分析;使用酶标仪进行OD值测量细胞增殖速率,并使用SPSS22.0统计数据。
7.一种由权利要求1~6任意一项所述生物因子涂层支架的制备方法制备的生物因子涂层支架,具有PDA涂层的Ni-Ti支架;具有肝素钠涂层的DA支架;具有VEGF涂层的DA-Hep支架;具有抗CD34抗体涂层的DA-Hep支架;不含肝素的支架;同时装载PDA、生物因子和肝素的支架。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110108199.XA CN112891642A (zh) | 2021-01-27 | 2021-01-27 | 一种生物因子涂层支架及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110108199.XA CN112891642A (zh) | 2021-01-27 | 2021-01-27 | 一种生物因子涂层支架及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112891642A true CN112891642A (zh) | 2021-06-04 |
Family
ID=76120530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110108199.XA Pending CN112891642A (zh) | 2021-01-27 | 2021-01-27 | 一种生物因子涂层支架及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112891642A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040065300A1 (en) * | 2002-10-02 | 2004-04-08 | Honda Giken Kogyo Kabushiki Kaisha | Engine speed control system for outboard motor |
CN104069547A (zh) * | 2014-07-24 | 2014-10-01 | 吉林大学 | 一种复合血管支架 |
CN107149702A (zh) * | 2017-05-12 | 2017-09-12 | 江南大学 | 一种聚多巴胺改性多孔支架的制备 |
CN109735819A (zh) * | 2019-03-14 | 2019-05-10 | 西南交通大学 | 具有NO催化释放与EPCs捕获功能的生物材料及其制备方法 |
CN110545754A (zh) * | 2017-04-13 | 2019-12-06 | 祥丰医疗私人有限公司 | 用聚多巴胺和抗体涂覆的医疗设备 |
-
2021
- 2021-01-27 CN CN202110108199.XA patent/CN112891642A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040065300A1 (en) * | 2002-10-02 | 2004-04-08 | Honda Giken Kogyo Kabushiki Kaisha | Engine speed control system for outboard motor |
CN104069547A (zh) * | 2014-07-24 | 2014-10-01 | 吉林大学 | 一种复合血管支架 |
CN110545754A (zh) * | 2017-04-13 | 2019-12-06 | 祥丰医疗私人有限公司 | 用聚多巴胺和抗体涂覆的医疗设备 |
CN107149702A (zh) * | 2017-05-12 | 2017-09-12 | 江南大学 | 一种聚多巴胺改性多孔支架的制备 |
CN109735819A (zh) * | 2019-03-14 | 2019-05-10 | 西南交通大学 | 具有NO催化释放与EPCs捕获功能的生物材料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
杨雷著: "《血管新生与细胞生长因子概论》", 30 September 2019 * |
谢槟等: "《基于多巴胺自聚合及肝素固定改善钛的血液相容性》", 《高等学校化学学报》 * |
韩晓军: "《生物功能化界面》", 31 January 2017 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gao et al. | Linker-free covalent immobilization of heparin, SDF-1α, and CD47 on PTFE surface for antithrombogenicity, endothelialization and anti-inflammation | |
Kottke-Marchant et al. | Effect of albumin coating on the in vitro blood compatibility of Dacron® arterial prostheses | |
CN102677032B (zh) | 一种在Ti表面固定载VEGF的肝素/多聚赖氨酸纳米颗粒的方法 | |
Chen et al. | Collagen/heparin coating on titanium surface improves the biocompatibility of titanium applied as a blood‐contacting biomaterial | |
CN101130114A (zh) | 植入式医疗器械的生物相容性表面涂层及其涂覆方法 | |
Xu et al. | Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles | |
US20090226600A1 (en) | Surface Coating Method and Coated Device | |
Dai et al. | Modifying decellularized aortic valve scaffolds with stromal cell-derived factor-1α loaded proteolytically degradable hydrogel for recellularization and remodeling | |
CN104758985B (zh) | 一种捕获内皮祖细胞EPCs的新型抗凝血支架涂层的制备方法 | |
CN112870437B (zh) | 具有抗凝抗增生及促内皮化的功能材料、其制备方法和应用 | |
CN104028434B (zh) | 一种在钛表面构建层粘连蛋白/肝素/SDF-1α抗凝及诱导内皮化多功能层的方法 | |
Yang et al. | Polydopamine-mediated long-term elution of the direct thrombin inhibitor bivalirudin from TiO 2 nanotubes for improved vascular biocompatibility | |
Li et al. | Coimmobilization of heparin/fibronectin mixture on titanium surfaces and their blood compatibility | |
Li et al. | Oriented immobilization of anti‐CD34 antibody on titanium surface for self‐endothelialization induction | |
Chen et al. | The fabrication of double-layered chitosan/gelatin/genipin nanosphere coating for sequential and controlled release of therapeutic proteins | |
AU2006288336A1 (en) | Tissue regeneration substrate | |
Wang et al. | Thermo-triggered ultrafast self-healing of microporous coating for on-demand encapsulation of biomacromolecules | |
CN105327406A (zh) | 一种制备多层载肝素还原氧化石墨烯涂层的方法 | |
ES2784924T3 (es) | Dispositivos médicos con trombogenicidad reducida | |
Lai et al. | Acellular biological tissues containing inherent glycosaminoglycans for loading basic fibroblast growth factor promote angiogenesis and tissue regeneration | |
Wang et al. | Construction of cytokine reservoirs based on sulfated chitosan hydrogels for the capturing of VEGF in situ | |
CN112891642A (zh) | 一种生物因子涂层支架及其制备方法 | |
CN113069588B (zh) | 一种多酚金属离子促凝涂层在制备止血材料上的应用 | |
WO2012121507A2 (ko) | 혈관내피 전구세포를 선택적으로 포획할 수 있는 스텐트 및 이의 제조 방법 | |
Tateshima et al. | Increased affinity of endothelial cells to NiTi using ultraviolet irradiation: An in vitro study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210604 |